Quick answers
- What is Mydayis?
- Mydayis is a brand name of Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate, a prescription medicine. The FDA NDC Directory lists 4 Mydayis products in 4 strengths and forms.
- Who makes Mydayis?
- Takeda Pharms USA holds the FDA application for Mydayis (NDA022063, approved June 20, 2017).
- Is there a generic or store brand of Mydayis?
- Yes. The FDA NDC Directory lists 26 other products with the same active ingredients, strength and form as a Mydayis product, 25 of them generic. Ask your pharmacist whether one is right for you.
- What do pharmacies pay for Mydayis?
- CMS lists a National Average Drug Acquisition Cost (NADAC) for 4 Mydayis strengths and forms (see the table below). That is what pharmacies pay to buy it, not what you pay: your price depends on your insurance and your pharmacy.
- Has Mydayis been recalled?
- No recall linked to Mydayis products (by their NDC code or label) appears in the FDA enforcement reports we use.
What Mydayis is
Each Mydayis product as listed in the FDA NDC Directory, by active ingredient, strength and form, with its official label. “Same medicine, other names” counts the other products with exactly the same active ingredients, strength and form (generic versions, store brands and other brands); inactive ingredients can differ.
Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate · prescription medicine
| Strength and form | Product names | Same medicine, other names | Label |
|---|---|---|---|
| amphetamine aspartate monohydrate 12.5 mg · amphetamine sulfate 12.5 mg · dextroamphetamine saccharate 12.5 mg · dextroamphetamine sulfate 12.5 mg capsule, extended release (oral) | Mydayis | 3 products, 3 companies | DailyMed |
| amphetamine aspartate monohydrate 3.125 mg · amphetamine sulfate 3.125 mg · dextroamphetamine saccharate 3.125 mg · dextroamphetamine sulfate 3.125 mg capsule, extended release (oral) | Mydayis | 3 products, 3 companies | DailyMed |
| amphetamine aspartate monohydrate 6.25 mg · amphetamine sulfate 6.25 mg · dextroamphetamine saccharate 6.25 mg · dextroamphetamine sulfate 6.25 mg capsule, extended release (oral) | Mydayis | 17 products, 15 companies | DailyMed |
| amphetamine aspartate monohydrate 9.375 mg · amphetamine sulfate 9.375 mg · dextroamphetamine saccharate 9.375 mg · dextroamphetamine sulfate 9.375 mg capsule, extended release (oral) | Mydayis | 3 products, 3 companies | DailyMed |
Its page lists every product and company, the FDA label’s uses and boxed warning, approvals, shortages and recalls: Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate →
FDA approval
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
| Application | Holder | First approved | Products |
|---|---|---|---|
| NDA022063 | Takeda Pharms USA | June 20, 2017 | 4 |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| amphetamine aspartate monohydrate 12.5 mg · amphetamine sulfate 12.5 mg · dextroamphetamine saccharate 12.5 mg · dextroamphetamine sulfate 12.5 mg capsule, extended release | Brand: Mydayis | $10.77 per capsule Generic of the same strength and form: $8.27 per capsule |
| amphetamine aspartate monohydrate 3.125 mg · amphetamine sulfate 3.125 mg · dextroamphetamine saccharate 3.125 mg · dextroamphetamine sulfate 3.125 mg capsule, extended release | Brand: Mydayis | $10.76 per capsule Generic of the same strength and form: $8.59 per capsule |
| amphetamine aspartate monohydrate 6.25 mg · amphetamine sulfate 6.25 mg · dextroamphetamine saccharate 6.25 mg · dextroamphetamine sulfate 6.25 mg capsule, extended release | Brand: Mydayis | $10.79 per capsule Generic of the same strength and form: $0.5625–$7.91 per capsule |
| amphetamine aspartate monohydrate 9.375 mg · amphetamine sulfate 9.375 mg · dextroamphetamine saccharate 9.375 mg · dextroamphetamine sulfate 9.375 mg capsule, extended release | Brand: Mydayis | $10.75 per capsule Generic of the same strength and form: $8.65 per capsule |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list Mydayis
The company named on the package (holder, repackager or distributor), as listed in the FDA NDC Directory, with its number of Mydayis products.
- Takeda Pharmaceuticals America, Inc.4 products
Recalls
No recall linked to Mydayis products (by their NDC code or label) appears in the FDA enforcement reports.
Sources
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug labeling (SPL, openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- NADAC (National Average Drug Acquisition Cost) 2026 — Centers for Medicare & Medicaid Services (CMS), data.medicaid.gov, list of November 4, 2026, retrieved November 7, 2026
Which names get a brand page: a name the NDC Directory lists for a medicine, held by one company (the FDA application holder, or the company named on most of its products), that is not just a description, and that is not the only product of its medicine.